• Giuseppe TridenteEmail author


Brentuximab vedotin (Adcetris™, Seattle Genetics; Takeda) is a chimeric IgG1k monoclonal antibody conjugated to the cytotoxic agent monomethyl auristatin E (MMAE). The complex (BV), targeting specifically CD30 (Ki-1 Ag; TNFRSF8), received an accelerated approval by FDA in 2011 for the treatment of relapsed Hodgkin’s lymphoma (HL), after failure of autologous stem cells transplantation (ASCT) or after at least two unsuccessful multiagent chemotherapy regimens in patients who are not candidates for ASCT. BV was also indicated for systemic anaplastic large cell lymphoma (sALCL) in post-chemotherapy relapse.


Progressive Multifocal Leukoencephalopathy Autologous Stem Cell Transplantation Infusion Reaction Mycosis Fungoides Progressive Multifocal Leukoencephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_11_MOESM1_ESM.xls (72 kb)
Supplementary material 1 (XLS 73 kb)


  1. 1.
    Adcetris™ (brentuximab vedotin). Prescribing Information. Seattle Genetics, 2012Google Scholar
  2. 2.
    Brentuximab vedotin (Adcetris™) BLA 125388/0 FDA Medical Review. 2011Google Scholar
  3. 3.
    Adcetris® (brentuximab vedotin) WC500135054 Assessment Report, EMEA, July 2012Google Scholar
  4. 4.
    Adcetris® (brentuximab vedotin) WC500135055 Product Characteristics Annex I Nov 2012Google Scholar
  5. 5.
    Horie H, Watanabe T (1998) CD30 expression in health and disease. Semin Immunol 10:457–470PubMedCrossRefGoogle Scholar
  6. 6.
    Chen Y-B, McDonough S, Hasserjian R et al (2012) Expression of CD30 in patients with acute graft-vs-host disease. Blood. doi: 10.1182/blood-2012-03-415422 Google Scholar
  7. 7.
    Sharman JP, Goldschmidt JH, Burke JM et al (2012) CD30 expression in nonlymphomatous malignancies. J Clin Oncol 30, 2012 (suppl; abstr 3069)Google Scholar
  8. 8.
    Brentuximab Vedotin Adis R&D profile (2011) Drugs 11:85–95Google Scholar
  9. 9.
    De Claro RA, McGinn KM, Kwitkowski VE et al (2012) U S Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large cell lymphoma. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-12-1803 PubMedGoogle Scholar
  10. 10.
    Furtado M, Rule S (2012) Emerging pharmacotherapy for relapsed or refractory Hodgkin’s lymphoma: focus on brentuximab vedotin. CMO Oncol 6:31–39Google Scholar
  11. 11.
    Diefenbach CSM, Leonard JP (2012) Targeting CD30 in Hodgkin lymphoma: antibody-drug conjugates make the difference. Am Soc Clin Oncol 1092–9118/10/1–10Google Scholar
  12. 12.
    Gopal AK, Ramchandren R, O’Connor OA et al (2012) Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 120:560–568PubMedCrossRefGoogle Scholar
  13. 13.
    Chen R, Palmer JM, Thomas SH et al (2012) Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with refractory relapsed or refractory Hodgkin lymphoma. Blood 119:6379–6381PubMedCrossRefGoogle Scholar
  14. 14.
    Kim WS (2012) Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol 5(S1):A2Google Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations